Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 31Advanced Solid Tumors 25Advanced Solid Tumor 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 15Solid Tumor 12Prostatic Neoplasms 12Multiple Myeloma 12Neoplasm Metastasis 11Recurrence 10Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Lung Neoplasms 9Stomach Neoplasms 8Melanoma 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Sarcoma 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Solid Tumors 6Carcinoma, Transitional Cell 5Advanced Solid Tumour 5Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Myelodysplastic Syndromes 4Lymphoma 4

Interventions

fluciclovine F-18 2Positron-Emission Tomography 2Injections 2Dexamethasone 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2tislelizumab 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1ricolinostat 1pomalidomide 1pembrolizumab 1lortalamine 1gossypol acetic acid 1daratumumab 1aflibercept 1Prednisone 1Oncolytic Virotherapy 1Octreotide 1Mitomycin 1Mammography 1Lenalidomide 1Ipilimumab 1Drug Delivery Systems 1Docetaxel 1Diagnosis, Computer-Assisted 1Daunorubicin 1Cytarabine 1Control Groups 1CPX-351 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Disease × Injections × Clear all
NCT04186845 2025-09-22

Spotlight

Blue Earth Diagnostics

Phase 3 Completed
391 enrolled 30 charts
Genitourinary

Disease, Prostatic Neoplasms

NCT04186819 2025-02-26

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Blue Earth Diagnostics

Phase 3 Completed
356 enrolled 28 charts
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡